1: (ROOT (S (NP (NNP Sorrento) (NNPS Therapeutics)) (VP (VP (VBZ skyrockets) (NP (CD 244) (NN %)) (PP (IN after) (S (VP (VBG claiming) (NP (NP (DT a) (NN breakthrough)) (PP (IN on) (NP (DT a) (CD COVI-19) (NN antibody)))))))) (NP (NNP Reuters) (NP (NNS Shares) (PP (IN of) (NP (NNP Sorrento) (NNP Therapeutics))))) (VP (VBD spiked) (NP (QP (RB as) (JJ much) (IN as) (CD 244)) (NN %)) (PP (IN on) (NP (NNP Friday))) (SBAR (IN after) (S (NP (DT the) (NN company)) (VP (VBD said) (SBAR (S (NP (NP (DT an) (NN antibody)) (SBAR (S (NP (PRP it)) (VP (VBD was) (VP (VBG developing)))))) (VP (VBD showed) (`` `) (NP (NML (CD 100) (NN %)) (NN inhibition)) ('' ') (PP (IN of) (NP (DT the) (CD COVI-19) (NN virus))) (PP (IN in) (NP (JJ preclinical) (NNS studies))))))))))) (. .)))
2: (ROOT (S (NP (DT The) (JJ small) (NN biotechnology) (NN company)) (VP (VBD said) (SBAR (S (NP (PRP it)) (VP (VBD aimed) (S (VP (TO to) (VP (VB create) (NP (`` `) (NP (NP (DT an) (NN antibody) (NN cocktail)) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (VB act) (PP (IN as) (NP (NP (DT a) (`` `) (JJ protective) (NN shield) ('' ')) ('' ') (PP (IN against) (NP (DT the) (NN coronavirus)))))))))))))))))) (. .)))
3: (ROOT (S (NP (NNP Sorrento)) (VP (VBD said) (SBAR (S (NP (NP (DT the) (JJ full) (NNS results)) (PP (IN of) (PP (IN from) (NP (PRP$ its) (NNS experiments))))) (VP (MD would) (VP (VB be) (`` `) (VP (VBN submitted) (PP (IN to) (NP (DT a) (ADJP (NN pee) (HYPH -) (VBN reviewed)) (NN publication))) (ADVP (RB shortly)))))))) (. .) ('' ')))
4: (ROOT (S (VP (VB Visit) (NP (NP (NNP Business) (NNP Insider) (POS 's)) (NN homepage)) (PP (IN for) (NP (JJR more) (NNS stories)))) (. .)))
5: (ROOT (S (NP (NNP Sorrento) (NNPS Therapeutics)) (VP (VBD skyrocketed) (NP (QP (RB as) (JJ much) (IN as) (CD 244)) (NN %)) (PP (IN on) (NP (NNP Friday))) (SBAR (IN after) (S (NP (DT the) (NN company)) (VP (VBD said) (SBAR (S (NP (NP (DT an) (NN antibody)) (SBAR (S (NP (PRP it)) (VP (VBD was) (VP (VBG developing)))))) (VP (VBD showed) (`` `) (NP (NML (CD 100) (NN %)) (NN inhibition)) ('' ') (PP (IN of) (NP (DT the) (HYPH COVI-19) (NN virus))) (PP (IN in) (NP (JJ preclinical) (NNS studies)))))))))) (. .)))
6: (ROOT (S (NP (DT The) (JJ small) (NN biotechnology) (NN company)) (VP (VBD said) (SBAR (S (NP (PRP it)) (VP (VBD planned) (S (VP (TO to) (`` `) (VP (VB generate) (NP (NP (DT an) (NML (NN antibody) (NN cocktail)) (NN product)) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (VB act) (PP (IN as) (NP (NP (DT a) (`` `) (JJ protective) (NN shield) ('' ')) (PP (IN against) (NP (NP (NNP SAR) (HYPH -) (CD Co-2)) (, ,) ('' ') (NP (NP (DT the) (JJ official) (NN name)) (PP (IN of) (NP (DT the) (JJ novel) (NN coronavirus)))))))))))))))))))) (. .)))
7: (ROOT (S (NP (NNP Sorrento)) (VP (VBD said) (SBAR (S (NP (PRP it)) (VP (MD would) (VP (VB ask) (NP (NNS regulators)) (PP (IN for) (NP (`` `) (NP (NP (NN priority) (NN evaluation)) (CC and) (NP (JJ accelerated) (NN review))) ('' ') (PP (IN of) (NP (PRP$ its) (NN antibody) (NN candidate)))))))))) (. .)))
8: (ROOT (S (NP (DT The) (NN company)) (VP (VBD added) (SBAR (IN that) (S (NP (PRP it)) (VP (VBD hoped) (S (VP (TO to) (VP (VP (VB receive) (NP (NN government) (NN support))) (CC and) (VP (VB partner) (PP (IN with) (NP (DT a) (JJ pharmaceutical) (NN company))) (S (VP (TO to) (VP (VB scale) (PRT (RP up)) (NP (NP (NN manufacturing)) (PP (IN of) (NP (PRP$ its) (NN candidate)))) (SBAR (IN if) (S (NP (JJ clinical) (NNS studies)) (VP (VBP find) (S (NP (PRP it)) (VP (TO to) (VP (VB be) (ADJP (JJ successful))))))))))))))))))) (. .)))
9: (ROOT (S (S (VP (VB Read) (NP (JJR more)))) (: :) (S (S (VP (VB Buy) (NP (NP (DT these) (CD 13) (NN tech) (NNS stocks)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VP (ADVP (RB abnormally)) (VBN disconnected) (PP (IN from) (NP (NP (NP (NNP Wall) (NNP Street) (POS 's)) (NNS expectations)) (PP (IN for) (NP (NN profit) (NN growth)))))) (CC and) (VP (VBN poised) (S (VP (TO to) (VP (VB rocket) (ADVP (RBR higher))))))))))))) (, ,) (NP (NNP Credit) (NNP Suisse)) (VP (VBZ says) (SBAR (S (NP (NNP Sorrento)) (VP (VBD said) (SBAR (S (NP (NP (DT the) (JJ full) (NNS results)) (PP (IN from) (NP (PRP$ its) (JJ preclinical) (NNS experiments)))) (VP (MD would) (VP (VB be) (`` `) (VP (VBN submitted) (PP (IN to) (NP (DT a) (ADJP (NN pee) (HYPH -) (VBN reviewed)) (NN publication))) (ADVP (RB shortly)))))))))))) (. .) ('' ')))
10: (ROOT (S (NP (NP (NNP Sorrento) (POS 's)) (NN market) (NN value)) (VP (VBD surged) ($ from$))))
11: (ROOT (S (S (NP (NNP Markets) (NNP Insider)) (VP (VB Read) (NP (JJR more)))) (: :) (S (NP (NP (DT A) (NML (JJ rea) (HYPH -) (NN estate)) (NN investor)) (SBAR (WHNP (WP who)) (S (NP (QP ($ generates$) (CD 34,000))) (PP (IN of) (NP (JJ annual) (NN cash) (NN flow)))))) (VP (VBZ shares) (NP (NP (PRP$ his) (JJ unique) (NN spin)) (PP (IN on) (NP (NP (DT a) (JJ popular) (NN investment) (NN strategy)) (SBAR (WHNP (WDT that)) (S (VP (VBZ 's) (VP (VBN helped) (S (VP (VB land) (NP (PRP him)) (NP (CD 114) (NNS units)))))))))))))))
